To improve the anti-solid tumor functions of iMACs, we used our previously established CAR-iMAC system, in which we stably expressed the first generation of anti-mesothelin (MSLN) CAR with CD3ζ as the intracellular domain in human iPSCs and differentiated them to produce MSLN-CAR-iMACs to kill mesothelin-expressing ovarian tumors both in vitro and in vivo10. Here, MSLN is linked to ovarian neoplasm.